Evidence map›Paper›PMID 34684841›Full record

ArticleMolecules (Basel, Switzerland)2021

The Influence of Antitumor Unsymmetrical Bisacridines on 3D Cancer Spheroids Growth and Viability.

Jolanta Kulesza, Monika Pawłowska, Ewa Augustin

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jolanta KuleszaDepartment of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdańsk University of Technology, 80-233 Gdańsk, Poland.ORCID 0000-0001-5024-4853
Monika PawłowskaDepartment of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdańsk University of Technology, 80-233 Gdańsk, Poland.ORCID 0000-0002-5914-1591
Ewa AugustinDepartment of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdańsk University of Technology, 80-233 Gdańsk, Poland.ORCID 0000-0002-0807-021X

Funding

National Science Center, Poland UMO-2016/23/B/NZ7/03324
6 · The paper itself

Abstract

The culture of 3D spheroids is a promising tool in drug development and testing. Recently, we synthesized a new group of compounds, unsymmetrical bisacridines (UAs), which exhibit high cytotoxicity against various human cell lines and antitumor potency against several xenografts. Here, we describe the ability of four UAs-C-2028, C-2041, C-2045, and C-2053-to influence the growth of HCT116 and H460 spheres and the viability of HCT116 cells in 3D culture compared with that in 2D standard monolayer culture. Spheroids were generated using ultra-low-attachment plates. The morphology and diameters of the obtained spheroids and those treated with UAs were observed and measured under the microscope. The viability of cells exposed to UAs at different concentrations and for different incubation times in 2D and 3D cultures was assessed using 7-AAD staining. All UAs managed to significantly inhibit the growth of HCT116 and H460 spheroids. C-2045 and C-2053 caused the death of the largest population of HCT116 spheroid cells. Although C-2041 seemed to be the most effective in the 2D monolayer experiments, in 3D conditions, it turned out to be the weakest compound. The 3D spheroid culture seems to be a suitable method to examine the efficiency of new antitumor compounds, such as unsymmetrical bisacridines.

Indexed as

Antineoplastic AgentsCell Culture TechniquesCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHCT116 CellsHumansNeoplasmsSpheroids, CellularAntineoplastic Agents2D and 3D culturesantitumor drugscancer treatmentcell deathspheroidsunsymmetrical bisacridines

Identifiers

PMID34684841
PMCPMC8538688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.